These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33461224)

  • 1. Cardiotoxicity and cardiac monitoring following the use of radiotheranostics agents including 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors.
    Jafari E; Amini AL; Ahmadzadehfar H; Bagheri D; Assadi M
    Nuklearmedizin; 2021 Apr; 60(2):99-105. PubMed ID: 33461224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of early oxidative stress following the use of radiotheranostics agents 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C.
    Jafari E; Ahmadzadehfar H; Bagheri D; Amini A; Assadi M
    Nucl Med Commun; 2021 Mar; 42(3):325-331. PubMed ID: 33306634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of indigenous
    Sitani K; Parghane RV; Talole S; Basu S
    Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.
    Severi S; Nanni O; Bodei L; Sansovini M; Ianniello A; Nicoletti S; Scarpi E; Matteucci F; Gilardi L; Paganelli G
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):881-8. PubMed ID: 23443937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
    Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J
    Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
    Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
    Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
    Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of receptor radionuclide therapy with
    Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival predictors of
    Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and outcomes of
    Lin E; Chen T; Little A; Holliday L; Roach P; Butler P; Hosking E; Bailey E; Elison B; Currow D
    Intern Med J; 2019 Oct; 49(10):1268-1277. PubMed ID: 31062490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
    Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
    Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L
    Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of
    Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
    Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy.
    Liu C; Liu T; Zhang J; Baum RP; Yang Z
    Clin Nucl Med; 2019 Nov; 44(11):876-878. PubMed ID: 31584494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.